Turnover: 3.03 billion EUR (2022)
Country: France
Created in 1929 under the name of Laboratoires Beaufour, the activities of IPSEN (Institut des Produits de Synthèse et d'Extraction Naturelle) have historically been based on natural plant-based medicines.this is illustrated by the success of Romarene, a medicine for digestive disorders made from Rosemary extracts, since the group's creation.
IPSEN groups the production of medicines under the "family health" segment, which accounts for 16% of the group's activity. In addition to its cutting-edge therapeutic activities, illustrated by its research partnerships with the CNRS and MIT, IPSEN is specialized in France in the gastroenterology and cognitive disorders markets. It is notably the creator of SMECTA and the sole distributor of Dysport since 1994.
IPSEN has historically focused on the Anglo-Saxon markets. Its flagship herbal product is SMEBIOCTA, a herbal solution to regulate intestinal flora.
The company is headed by David Meek.
Financial Data
DUNS: 308197185
Legal Name: IPSEN PHARMA
Address: 65 QUAI GEORGES GORSE , 92100 BOULOGNE-BILLANCOURT
Number of employees: Entre 500 et 999 salariés (2020)
Capital: 7 755 053 EUR
Financial Data:
| Year | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|
| Turnover | 1 635 000 000 | 1 567 000 000 | 1 536 600 000 | 1 340 000 000 | 1 206 000 000 | 1 084 567 984 | 1 038 847 015 |
| Gross margin (€) | 1 303 900 000 | 1 270 800 000 | 1 158 400 000 | 1 087 500 000 | 945 100 000 | 808 112 464 | - |
| EBITDA (€) | 400 700 000 | 464 400 000 | 320 900 000 | 212 200 000 | 172 500 000 | 183 046 982 | - |
| Operating profit (€) | 306 500 000 | 338 200 000 | 244 500 000 | 144 000 000 | 112 400 000 | 155 291 033 | - |
| Net profit (€) | 96 000 000 | 222 000 000 | 345 200 000 | 127 000 000 | 233 000 000 | 178 518 785 | 185 808 126 |
| Turnover growth rate (%) | 4,3 | 2,1 | 14,7 | 11 | 11,3 | 4,4 | - |
| Ebitda margin rate (%) | 24,5 | 29,6 | 20,9 | 15,8 | 14,3 | 16,9 | - |
| Operating margin rate (%) | 18,7 | 21,6 | 15,9 | 10,7 | 9,3 | 14,3 | - |
| Working Capital (turnover days) | -217,5 | -229,3 | -88,2 | -62 | -67 | -144,5 | - |
| Working Capital requirements (turnover days) | 29,4 | 44,9 | 35,8 | 18,1 | 16 | 35,8 | - |
| Net margin (%) | 5,9 | 14,2 | 22,5 | 9,5 | 19,3 | 16,5 | - |
| Added value / Turnover (%) | 31,1 | 35,6 | 28,4 | 17,6 | 18,4 | 21,4 | - |
| Wages and social charges (€) | 122 900 000 | 111 300 000 | 107 600 000 | 141 600 000 | 136 300 000 | 127 177 208 | - |
| Salaries / Turnover (%) | 7,5 | 7,1 | 7 | 10,6 | 11,3 | 11,7 | - |
Company Managers:
| Position | First Name | Last Name | Age | |
|---|---|---|---|---|
| Président | David | LOEW | 56 | |
| Directeur général | François-Maurice | GARNIER | 60 | |
| Directeur général | Aidan | MURPHY | 56 | |
| Directeur général | Stéphane | ANDRE | 64 | |
| Directeur général | Stéphane | SIMON | 53 | |
| Directeur général | Régis | MULOT | 56 | |
| Directeur général | Henri | GUENARD | 43 | |
| Directeur général | Aymeric | LE CHATELIER | 53 | |
| Directeur général | Patrice | ZAGAME | 62 | |
| Directeur général | Bartosz, Daniel | BEDNARZ | 52 | |
| Directeur général | Philippe | DE SORBIER DE POUGNADORESSE | 50 | |
| Directeur général | Howard | MAYER | 60 |
Studies mentioning this company
The herbal medicine market - France
Other companies mentioned:
- Arkopharma
- Bayer
- Ipsen
- https://www.sante-verte.com/fr/
- Merck KGaA
- Nutreov
- PiLeJe
- Groupe Fenioux
- Natur House
- Puressentiel France
- Pranarôm
- Naturactive (Pierre Fabre)
The aesthetic medicine market - United Kingdom
Other companies mentioned:
- Allergan plc
- Ipsen
- Merz Pharmaceuticals
- Cynosure
- Alma Lasers
The aesthetic medicine market - Italy
Other companies mentioned:
- Fidia Farmaceutici
- Decomedical
- ITS Group
- BTL
- EME Estetica
- Ipsen
- Merz Pharmaceuticals
- Allergan plc